Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial (Q42654585)

4 November 2017

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial (English)

1 reference

4 November 2017

0 references

1 reference

1 reference

1

Michaela Diamant

1 reference

4 November 2017

Luc Van Gaal

2

1 reference

4 November 2017

Bruno Guerci

3

1 reference

4 November 2017

Stephen Stranks

4

1 reference

4 November 2017

Jenny Han

5

1 reference

4 November 2017

Jaret Malloy

6

1 reference

4 November 2017

Marilyn K Boardman

7

1 reference

4 November 2017

Michael E Trautmann

8

1 reference

4 November 2017

4 April 2014

1 reference

The Lancet: Diabetes & Endocrinology

4 November 2017

1 reference

4 November 2017

2

1 reference

4 November 2017

464-473

1 reference

4 November 2017

6

1 reference

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Development of a brief measure to assess quality of life in obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

The assessment of binge eating severity among obese persons.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noni

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Basal insulin supplementation in type 2 diabetes; refining the tactics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970029-4

7 January 2021

10.1016/S2213-8587(14)70029-4

Identifiers

DOI

1 reference

4 November 2017

1 reference